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I.  INTRODUCTION 
Each year scientists uncover new mysteries, make miraculous discoveries, and 
perfect processes that will aid them in curing thousands of debilitating and fatal 
diseases.  In the past century, several of the most fascinating discoveries were made 
in the field of genetic research.  For instance, in 1997, scientists cloned a sheep.  The 
infamous cloned sheep became known as Dolly. 
The importance of genetic research today is overwhelming.  Although genetic 
research presents many legal and ethical concerns, the benefits drastically outweigh 
the costs.  For instance over 140 million people stand to benefit from human 
embryonic stem cell research, including those Americans suffering from Parkinson’s 
and Alzheimer’s disease.1 
In an attempt to quell the legal and ethical concerns associated with genetic 
research, legislation has been developed and several administrative committees have 
been formed.  The present restraints placed on the field of genetic research by the 
Legislature and the administrative committees are sufficient to deal with the legal 
and ethical issues raised. 
This Note will focus on the medical achievements that have been made, in large 
part, because of advances in genetic research.  Specifically, this Note will focus on 
the genetic advances associated with the Human Genome Project, Gene Therapy, 
Genetic Testing, and Human Embryonic Stem Cell Research. 
The last year of the twentieth century brought scientists one step closer to the 
successful completion of the Human Genome Project.2  The Human Genome Project 
is a government-funded project with the underlying goal of sequencing and mapping 
the entire human genome.3  Scientists believe that the completion of this project will 
aid them in answering many questions associated with diseases currently afflicting 
thousands of Americans.4 
Additionally, researchers have made significant advances in the science of gene 
therapy.  Researchers have developed a method referred to as gene replacement 
therapy.  Through the use of gene replacement therapy researchers will be able to 
replace incorrect genetic material contained in a cell with the correct genetic 
material.5  In addition to gene replacement therapy, scientists have also discovered a 
method of gene therapy that instructs a cell to internally correct a genetic mistake.6 
Genetic testing is another area in which scientists have made important advances.   
One advance is the availability of genetic testing for familial polyposis and non-
                                                                
1Glenn McGee, Bioethics at the End of the 1900’s, at http://www.msnbc.com/ 
news/336361.asp (website expired) [hereinafter McGee I]. 
2See id. 
3H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179. 
4M. Warman, Maps in the Study of Genetic Variation and Human Phenotypes, at 
syllabus.cwru.edu [hereinafter Warman I]. 
5LYNN B. JORDE ET AL., MEDICAL GENETICS 283 (2d ed. 1999). 
6Lisa Laurence, Gene Therapy Breakthroughs Delight Geneticists, at 
http://www.genesage.com/geneletter/0299/genetherapybreakthrough.html (website expired). 
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hereditary ployposis colon cancer.7  Genetic testing is extremely important, because 
research has proven that early disease detection can drastically improve the quality 
and longevity of life.8   
In November 1998, scientists isolated stem cells in early human embryos.9  
Researchers feel this discovery will lead them to possible therapies for diseases such 
as Parkinson’s and Alzheimer’s.10  Furthermore, scientists feel that they will be able 
generate human organs from isolated stem cells.11  This development will enhance 
the therapeutic advantages of transplantation science.  Those individuals drastically 
in need of organ transplants will no longer have to wait for an organ.  With the 
ability to generate organs, doctors can help more patients, and significantly reduce 
the number of deaths associated with the unavailability of organs for use in 
transplantation surgeries. 
In addition to discussing the benefits of genetic research, this Note will outline 
some of the ethical and legal concerns associated with the field of genetic research.  
The most prevalent concerns associated with advances in genetic research center 
around the availability of genetic information and how this information will effect 
privacy rights and employment and insurance practices.  There are several other 
concerns and many other benefits associated with genetic research; however, this 
Note does not encompass them.  The availability of genetic information has caused 
people to become concerned about their privacy.12  Additionally, individuals are 
concerned about how genetic information will be used by insurance providers in 
determining insurance coverage.13  Similarly, the use of genetic information in 
employment practices presents another concern associated with the availability of 
genetic information.14 
There are special concerns associated with human embryonic stem cell research.  
Stem cells are isolated from human embryos.15  Therefore, a major controversy 
associated with human embryonic stem cell research is the destruction of potential 
human life.16  A secondary concern is that human embryonic stem cell research will 
encourage women to have abortions.17  This Note will demonstrate how both of these 
concerns are unwarranted. 
                                                                
7Monique K. Mansoura & Francis S. Collins, Medical Implications of the Genetic 
Revolution, 1 J. HEALTH CARE L. & POL’Y 329, 341 (1998). 
8Id.; Louis J. Elsas II, A Clinical Approach to Legal and Ethical Problems in  Human 
Genetics, 39 EMORY L.J. 811, 825 (1990). 
9McGee I, supra note 1, at 2. 
10Id. 
11Id.; Dorthy C. Wertz, Human Embryonic Stem Cells: A Source of Organ Transplants, at 
http://www.genesage.com/geneletter/0299/humanembryonicstemcells.html (website expired). 
12H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179. 
13Id. 
14Id. 
15Wertz, supra note 11. 
16Id. 
17Id. 
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Even though there are some ethical and legal issues associated with genetic 
research, further restrictions should not be placed on the field.  This Note will 
discuss how the present limitations placed on the field of genetic research, by the 
Legislature and administrative committees, are sufficient to effectively suppress the 
aforementioned ethical and legal concerns. 
The Genetic Privacy Act and the Genetic Privacy and Non-Discrimination Act 
have been developed to address the issues previously raised.18  The Americans with 
Disabilities Act is broad enough to cover concerns about the use of genetic 
information in employment practices.19  The Health Insurance Portability and 
Accountability Act of 1996 addresses problems associated with the use of genetic 
information by insurance providers.20 
Additionally, several committees have been developed to specifically address the 
issues raised by genetic research.  For example, the National Institute of Health and 
the Department of Energy developed the formal Ethical, Legal and Social Issues 
[hereinafter “ELSI”] programs.21  These administrative committees are responsible 
for making policy recommendations to federal and state legislatures.22 
The benefits of genetic research clearly outweigh the costs.  The present 
limitations placed on the field, by the Legislature and administrative committees, are 
sufficient to effectively quash the concerns. 
II.  SCIENTIFIC BACKGROUND 
The study of genetics dates back to the discovery of the human chromosome in 
1870.23  Following this important discovery, scientists determined that most human 
traits were heritable.24  By the early twentieth century, Gregor Mendel developed his 
law of inheritance.25  This law of inheritance became known as Mendelian 
inheritance.26  With the development of Mendelian inheritance, the term “gene” was 
used to define the fundamental unit of heredity.27 
                                                                
18George J. Annas, et al., The Genetic Privacy Act and Commentary (1995), at  
http://www.ornl.gov/hgmis/resource/privacy/privacy1.html; Michael M. J. Lin, Conferring a 
Federal Property Right in Genetic Material: Stepping into the Future with the Genetic 
Privacy Act, 22 AM. J.L. & MED. 109, 127, 129 (1996). 
19Mansoura, supra note 7, at 344; Anne Lawton, Regulating Genetic Destiny: A 
Comparative Study of Legal Constraints in Europe and the United States, 11 EMORY INT’L L. 
REV. 365, 398-404 (1997). 
20Mansoura, supra note 7, at 344. 
21H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179 (Leg. Hist.). 
22Mansoura, supra note 7, at 344. 
23M. Warman, Human Genetics, at syllabus.cwru.edu [hereinafter Warman II]. 
24Id. at 3. 
25Id. 
26Id. 
27Id. 
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Expanding on Mendelian inheritance, Oswald Avery discovered that 
deoxyribonucleic acid or DNA is the chemical basis for inheritance.28  The unveiling 
of DNA as the chemical basis for inheritance encouraged scientists to ascertain the 
structure of this molecule.  James Watson and Francis Crick eventually unearthed the 
structure of DNA.29  Watson and Crick determined that the structure of this molecule 
represented a winding ladder.30  Therefore, the structure of DNA became known as a 
“double helix.”31   
Each prong of the winding ladder represents a gene and is composed of 
nucleotides.32  There are four nucleotides that make up a DNA sequence:33  adenine, 
guanine, cytosine, and thymine.34  The nucleotides are held together by weak bonds, 
and once bonded they become known as base pairs.35  Base pairs consist of adenine-
thymine bonds and guanine-cytosine bonds.36  The organization of these base pairs 
delineates the type of information a gene or piece of DNA will carry.37 
Once scientists codified DNA as the chemical basis for inheritance and 
determined that genes are the fundamental unit of heredity, the term “genome” was 
coined to refer to the total amount of genes and DNA found within an organism.38  
Scientists have yet to determine exactly how many genes are in the human genome; 
however, researchers estimate the number to be between 75,000 and 100,000.39 
After scientists came to understand the process of heredity, they moved on to 
more fascinating topics.  Researchers began to ascertain why disease affects certain 
individuals and not others.  Additionally, research established that all genetic 
disorders and many other diseases result from a mutation or change within the DNA 
sequence of a genome.40  This change or mutation can be dramatic or slight.41   Genes 
are comprised of base pairs, and scientists estimate that there are approximately three 
billion base pairs in the human genome.42  Consequently, there are about three billion 
genetic loci that can be mutated.43  Because researchers have concluded mutations 
                                                                
28Warman II, supra note 23, at 3. 
29Id. 
30Id. 
31Id. 
32H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179. 
33Id.  (a DNA sequence is composed of several genes). 
34Id. 
35Id. 
36Id. 
37H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179. 
38Warman II, supra note 23, at 3. 
39Id. 
40Id. 
41Id. 
42Id. 
43Warman II, supra note 23, at 3. 
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are the root of many debilitating and fatal disorders, one can see the vast importance 
of enhanced genetic research. 
III.  BENEFITS OF GENETIC RESEARCH 
A.  The Human Genome Project 
Every individual carries at least twenty harmful genes.44  Until recent 
developments in genetics, physicians have been unable to identify these harmful 
genes.45  Recognizing this immense problem, Congress developed the Human 
Genome Project.  The Human Genome Project is federally funded and operated 
jointly by the National Institutes of Health and the Department of Energy.46  Because 
of the medical and scientific importance of this project, Congress apportioned 
approximately $3 billion, or about $200 million per year for fifteen years to aid in its 
completion.47 
The ultimate goal of the Human Genome Project is to sequence, map, and decode 
the entire human genome.  Researchers are striving to reach this goal by creating 
comprehensive linkage maps, disease maps, gene maps, physical maps, radiation 
hybrid maps, and body maps.48  Scientists believe that these maps will prove to be 
extremely useful in disease gene discovery.49  Researchers explain that one can look 
at a genetic map to determine if other investigators have independently placed a 
disease gene in the same region as the corresponding disease locus.50  If the disease 
gene is placed in the same region as the disease locus, the gene becomes a candidate 
for causing the disease.51  Once the gene is determined to be a disease-causing 
candidate, scientists can test the gene to ascertain if it is actually responsible for a 
particular disease.52 
Through mapping, researchers were able to identify the disease gene responsible 
for causing Huntington’s Disease, or HD.53  Huntington’s Disease is believed to 
effect an estimated three to eleven out of every 100,000 persons.54  The disease 
normally presents itself in patients sixty-years old and older.55  Only five percent of 
patients afflicted with Huntington’s Disease present symptoms in the first decade of 
                                                                
44Aubrey Milunsky, The “New” Genetics: From Research to Reality, 27 SUFFOLK U. L. 
REV. 1307, 1310 (1993). 
45Id. at 1310. 
46H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179.   
47Id. 
48Warman I, supra note 4, at 5. 
49Id. 
50Id. 
51Id. 
52Id. 
53Warman I, supra note 4, at 3. 
54Id. 
55Id. 
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their lives.56  Huntington’s Disease is an extremely debilitating disease; HD patients 
suffer from progressive dementia, involuntary movements, and physchiatric 
disturbances.57  Before the HD gene was isolated, physicians lacking conclusive 
evidence of a family history of Huntington’s Disease would spend months to years 
attempting to determine whether an individual was afflicted with this disease.58  Now 
that researchers have identified the disease-causing gene, individuals can be rapidly 
diagnosed for HD.59  Rapid diagnosis is not a cure, but it will allow physicians to 
improve the patient’s quality of life. 
On Monday, June 26, 2000, scientists announced the completion of the first 
rough map of the human genetic code.60  Over ninety-seven percent of the human 
DNA is now mapped.61  This is an amazing accomplishment, and it was completed 
ahead of schedule.  
The next step in the Human Genome Project is to identify the individual gene and 
the proteins that make up the gene.62  This process will allow geneticists to 
understand how the gene functions, why some genes cause disease, and how to 
develop therapies and cures for thousands of life-threatening diseases.63 
Even though the Human Genome Project is only partially complete, many 
disease-causing genes have been placed in the same region as the corresponding 
disease locus.64  Obviously, the importance of the Human Genome Project is 
immense.  Researchers believe that vast amounts of beneficial scientific information 
will be gained from this project, and as we all know:  “knowledge equals power.”65  
Therefore, researchers need the freedom to complete this project. 
B.  Gene Therapy 
Gene therapy is the “genetic alteration of the cells of individuals with genetic 
diseases.”66  Gene therapy targets two types of cells:  germ cells and somatic cells.67   
                                                                
56Id. 
57Id.  Those patients under twenty years of age present with a rapid progression of 
bradykinesia, rigidity, epilepsy, and severe dementia.  Warman I, supra note 4, at 3. 
58Milunsky, supra note 44, at 1308. 
59Id. 
60Charlene Cairo, Scientists Complete Genetic Milestone (June 26, 2000), at 
http://www.msnbc.com/news/424682.asp. 
61Id. 
62Id. 
63Id. 
64Warman I, supra note 4, at 3. 
65Julia Walsh, Reproductive Rights and the Human Genome Project, 4 S. CAL. REV. L. & 
WOMEN’S STUD. 145, 147 (1994). 
66JORDE, supra note 5, at 283. 
67Walsh, supra note 65, at 149. 
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Somatic cells include all cells in the body, except sperm and egg cells; whereas germ 
cells include only sperm and egg cells.68   
Somatic cell gene therapy is the alteration of human somatic cells in order to treat 
a specific disorder.69  As previously stated, somatic cells include all body cells, 
except sperm and egg cells.  Although somatic cells are all inclusive, bone marrow 
stem cells seem to be the prime candidates for stem cell gene therapy.70  Somatic cell 
gene therapy protocols are currently being tested for a number of disorders.71  Below 
is a partial list of diseases for which somatic cell gene therapy is being tested: 
 
Disease Target Cell Inserted Gene 
ADA deficiency Bone marrow stem cells Adenosine deaminase 
Hemophilia B Hepatocytes Factor IX 
Cystic Fibrosis Airway epithelial cells CFTR 
Malignant melanoma Melanoma tumor cells HLA-B7 gene 
Duchenne Muscular Dystrophy Myoblasts Dystrophine  
Lung cancer Lung cancer cells Normal p53 
Brain tumors Brain cells Herpes thymine kinase 
Ovarian cancer Ovarian cancer cells Herpes thymine kinase 
AIDS Helper T lymphocytes Dominant negative  
   retrovirus mutations 72 
 
The most commonly used technique in somatic cell gene therapy is gene 
replacement.  Gene replacement therapy is the replacement of a missing gene 
product by inserting a normal gene product into the cell.73  Geneticists insert the new 
genetic material into the cell through the use of a viral carrier.74  This viral carrier 
enters the nucleus of the cell and deposits the normal gene product into the cell.75  
Researchers explain that even a partially effective gene therapy may provide 
significant health benefits.76 
Focusing on diseases like hemophilia, cystic fibrosis, and phenylketonuria or 
PKU, researchers have developed a technique that prompts liver cells to change their 
own DNA sequences.77  Scientists explain that genes are composed of nucleotides, 
and that missing even one nucleotide can cause drastic results.78  For instance, 
hemophiliacs are missing the nucleotide responsible for directing liver cells to 
                                                                
68Id. 
69JORDE, supra note 5, at 283. 
70Id. 
71Id. 
72Id. 
73Id. 
74JORDE, supra note 5, at 283. 
75Id. 
76Id.. 
77Laurence, supra note 6. 
78Id. 
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produce an important blood-clotting protein.79  Like hemophilia, many genetic 
disorders are caused by single nucleotide mutations.80 
Dr. Clifford Steer of the University of Minnesota Medical School, determined 
that the mutation causing hemophilia occurs on the factor IX gene.81  Relying on this 
information, Dr. Steer and his team designed a molecule that can travel into the liver 
cells of rats.82  Once inside the nucleus of a liver cell, the molecule can direct the 
cell’s internal mechanisms to correct the “clotting” nucleotide on the factor IX 
gene.83  This special molecule is referred to as “chimeric RNA/DNA 
oligonucleotide.”84  Chimeric RNA/DNA oligonucleotide is composed of genetic 
material containing a “correction;” the correction mandates the cell to change its 
DNA.85 
In simpler terms, this special molecule can be compared to a correction key on a 
typewriter.86  The molecule alerts the cell to a mistake in its DNA sequence, then the 
cell corrects the mistake by “writing over” the incorrect nucleotide or nucleotides.87  
In hemophiliacs the factor IX gene has a cytosine, “C,” in place of adenine, “A.”88  
Chimeric RNA/DNA oligonucleotide instructs the cell to replace the “C” with an 
“A.”89  This molecule has the power to correct, insert, or delete up to three 
nucleotides.90 
Dr. Steer and his team have also performed a similar procedure to correct the 
genetic mutation that causes the rodent equivalent of Crigler-Najjar syndrome.91  
Crigler-Najjar syndrome, like hemophilia, affects the liver.92  Children born with this 
disease are unable to metabolize the protein billirubin.93  Consequently, these 
children suffer from brain damage and will ultimately succumb to an early death.94  
The procedure developed by Dr. Steer and his team will assist researchers in creating 
therapies to cure and treat the most debilitating diseases, like Crigler-Najjar 
syndrome. 
                                                                
79Id. 
80Id. 
81Id. 
82Laurence, supra note 6. 
83Id. 
84Id. 
85Id. 
86Id. 
87Laurence, supra note 6. 
88Id. 
89Id. 
90Id. 
91Id. 
92Laurence, supra note 6. 
93Id. 
94Id. 
130 JOURNAL OF LAW AND HEALTH [Vol. 15:121 
A major difference between Dr. Steer’s method and traditional gene therapy is 
the use of a chimeric RNA/DNA oligonucleotide in the place of a viral carrier to 
deliver the genetic material to the target cell.95  The procedure developed by Dr. 
Steer and his team is referred to as chimeraplasty.96  Chimeraplasty is directed at 
somatic cells not germ cells, therefore the results are not heritable.97  Dr. Steer and 
his team are confident that chimeraplasty will be used to cure liver-based diseases in 
the future.98  Furthermore, Dr. Steer expects this method to be applicable not only to 
stem cells found in the liver, but also to those found in the bone marrow, nervous 
system, renal system, and the muscular system.99 
Another type of gene therapy is germline therapy.  Germline therapy involves the 
modification of all cells in the body, including those cells that produce gametes.100  
Germline therapy affects those cells involved in reproduction, therefore scientists can 
alter heritable traits.101  Furthermore, because germline therapy involves gametes, the 
alterations made are inheritable.102  Therefore, any changes made through germline 
therapy can be passed from the recipient to his offspring.103   
The ability of scientists to alter future generations has been the root of much 
controversy surrounding gene therapy.  Many argue that researchers should not be 
able to change the traits of an individual prior to birth, without his consent.  Putting 
this controversy aside, germline therapy is essential to the early treatment of genetic 
disorders.104 
Although no one has been cured by gene therapy as of yet, researchers explain 
that this genetic advancement has had some positive effects on individuals afflicted 
with many diseases.105  Even though criticism surrounds the area of gene therapy, 
research illustrates that this procedure may be the most effective treatment available 
for many human diseases.106 
C.  Genetic Testing 
There are three main types of genetic tests available today: screening tests, 
diagnostic tests, and predictive or pre-symptomatic tests.107  With the increasingly 
                                                                
95Id. 
96Id. 
97Laurence, supra note 6. 
98Id. 
99Id. 
100JORDE, supra note 5, at 287.  Gametes are sperm egg cells.  Id. 
101Id.; see also Walsh, supra note 65, at 149. 
102Walsh, supra note 65, at 149. 
103Id. 
104Id. 
105Id. 
106Id. 
107M. Warman & S. Schwartz, Genetic Testing, at syllabus.cwru.edu [hereinafter Warman 
III].  
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large number of diseases afflicting individuals today, genetic testing has become 
extremely important. 
Genetic screening is used to classify seemingly healthy individuals who are at 
risk for the developing diseases.108  Newborn screening is used to determine whether 
a newborn is afflicted with or is a carrier of a particular disease.109  Normally this 
procedure is done within the first twenty-four to seventy-two hours of life.110  
Newborn screening allows physicians to begin treatment early, thereby, adding years 
and quality to an individual’s life. 
Newborn screening has proven to be extremely effective in treating many genetic 
disorders.  Phenylketonuria is a genetic disorder that can be controlled through diet if 
caught early.111  PKU causes mild to severe mental retardation in-patients afflicted 
with this disease.112  The symptoms of PKU resemble developmental delay, therefore 
it is difficult for physicians to detect.113  If a newborn is screened for PKU and tests 
positive, physicians can regulate the child’s diet.114  Research has shown that 
beginning a low phenyalanine diet, before four weeks of age, is highly effective in 
altering the course of this disease.115  In fact, individuals on this diet can expect to 
develop normal intelligence.116  Newborn screening is essential in the early detection 
and treatment of diseases, like PKU. 
Carrier screening is used to determine what members of a population are carriers 
of genetic disorders.117  Carrier screening gives physicians the ability to determine 
whether an individual is a carrier of a disease-causing gene.  If an individual is found 
to be a carrier of a disease-causing gene, doctors can make counseling 
recommendations.118  Furthermore, carrier screening can alert potential parents that 
they may pass a disease gene to their offspring.119  Carrier screening is a tool that 
assists doctors in ensuring that dangerous disease causing genes are not passed into 
new generations.  
Carrier screening also aids researchers in determining what populations are more 
susceptible to a particular disease.  Through carrier screening, researchers have 
determined that one in twenty-five Caucasians carry the gene for cystic fibrosis, 
                                                                
108Id. at 2-3. 
109Id. 
110Id. 
111JORDE, supra note 5, at 268 (PKU affects approximately one in 10,000 to 15,000 
Caucasian births). 
112Id.  (Approximately 95% of patients suffering from PKU who go untreatedwill develop 
mild to severe mental retardation.). 
113Id. 
114Id. 
115Id. 
116JORDE, supra note 5, at 268. 
117Id. 
118Milunsky, supra note 44, at 1310-11. 
119Id. 
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about one in twelve people of Mediterranean decent carry the gene for thalassemia, 
about one in ten African Americans carry the gene for sickle-cell anemia, and about 
one in thirty Ashkenazi Jews carry the gene for Tay-Sacs disease.120  Monitoring 
disease gene distribution over given populations will allow researchers to determine 
why certain individuals succumb to certain diseases.   
Although genetic screening tests are medically and scientifically beneficial, they 
are not conclusive.121  Once the presence of a disease-causing gene is suspected in an 
individual, physicians recommend diagnostic testing.122  Diagnostic testing is used to 
confirm the presence of a disease-causing gene.123   
In contrast, pre-symptomatic or predictive testing is used on healthy individuals 
who may have a family history of disease.124  Pre-symptomatic or predictive testing 
is done before the individual presents any signs of a disease.125  Consequently, results 
from this method of genetic testing can cause psychological or physical harm.126  
This method of testing raises concerns about privacy and confidentiality, in that it is 
a method of looking into the future.127  Many fear that predictive or pre-symptomatic 
testing will make genetic information available for use by employers, insurance 
providers, and health care providers.128  This is a prevalent concern because the 
genetic information can forecast the future; therefore insurance providers and 
employers can make decisions based on future events.   
Many case studies establish that genetic testing can save thousands of lives.  For 
example, early diagnosis of colon cancer can be life saving.  Genetic testing for the 
disease-causing gene for colon cancer is now available.129  Patients testing positive 
for one copy of the autosomal gene responsible for causing colon cancer can undergo 
life saving surgery.130  Surgeons can perform a colonectomy or can remove colon 
adenomas before symptoms of the disease become present.131  Both of these 
procedures effectively prevent colon cancer.132  In addition to colon cancer, early 
diagnosis and treatment are successful tools in the prevention of many other diseases, 
                                                                
120Id. 
121Warman III, supra note 107, at 3. 
122Id. 
123Id. 
124Id. 
125Id. 
126Warman III, supra note 107, at 3. 
127Milunsky, supra note 44, at 1312. 
128Id. 
129Id. 
130H.R. REP. NO. 102-478 (1992), available at 1992 WL 74179. 
131Id. 
132Id. 
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such as PKU.133  Early diagnosis and treatment of disease can eliminate thousands of 
needless and painful deaths.   
Even though genetic testing raises concerns over privacy, such as genetic 
information being disclosed to an unauthorized source, and the use of such test 
results by insurance providers and employers, the benefits outweigh the risks.  Early 
diagnosis and treatment of disease prevents thousands of deaths; genetic testing 
assists physicians in this process.  In response to the concerns, federal legislation has 
been developed to safeguard the privacy of genetic information and to ensure that 
employers and insurance providers do not misuse it. 
IV.  HUMAN EMBRYONIC RESEARCH 
Human embryonic research is extremely important in the advancement of 
transplantation science.  Findings show that in 1997 approximately 56,000 people in 
the United States were awaiting organ transplants.134  The United Network for Organ 
Sharing explains that approximately 4000 of the 56,000 Americans awaiting organ 
transplants died because of the unavailability of organs.135  The decreasing number of 
organs available for transplantation has caused bioethicists to suggest paying people 
for organ donations.136  In some countries, organ shortages have lead to mandatory 
organ donation and the removal of organs from living persons.137   
Presently, the problem in the United States has not lead to mandatory organ 
donation, but researchers predict that if families do not begin to donate organs of the 
deceased, drastic measures will need to be taken.138  Researchers suggest that using 
isolated human embryonic stem cells to grow organs may solve this problem.139  At 
the present time, researchers are not exactly sure how to create organs from isolated 
stem cells, but they expect to know in the near future.140  Once scientists determine 
how to make organs from isolated stem cells, organs will be readily available for 
transplantation, and thousands of deaths will be prevented.141 
A.  Benefits of Human Embryonic Research 
Although human embryonic research has sparked a significant amount of 
controversy, many positive scientific and medical advances have been made in the 
field.  Possibly the most significant advancement is the isolation and growth of 
embryonic cells that are capable of developing into organs.142  Human embryonic 
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stem cells can develop into many different organs when given the proper genetic 
instructions.143 
On November 6, 1998, the New York Times reported that two research groups, 
one headed by Dr. James A. Thomson of the University of Wisconsin, Madison and 
the other headed by Dr. John Gearhart of Johns Hopkins University, Baltimore, 
succeeded in growing human stem cells in a laboratory.144  Many hope that 
researchers will be able to use these stem cells to generate human organs.145 
The research groups isolated the human embryonic stem cells using two different 
procedures.  Dr. Thomas’ group removed stem cells from a fifteen to twenty cell 
“pre-embryo” called a blastocyst.146  The stem cells were taken from the blastocysts 
approximately three days after fertilization.147  At this stage, each stem cell has the 
potential to become many different parts of the body, and is referred to as 
pluripotent.148  During the blastocyst stage these stem cells are identical, therefore it 
is impossible to determine whether a particular cell will become an embryo or a 
placenta.149  
Dr. Gearhart and his research team isolated stem cells from the germ cells of 
aborted fetuses.150  Unlike other embryonic cells, germ cells are not committed to 
becoming a particular organ.151  Therefore, scientists can use genetic material to 
instruct the isolated stem cell to develop into any organ.152  Regardless of the method 
of isolation, researchers believe that the isolated stem cells are identical, and will be 
extremely useful in advancement of transplantation science.153 
B.  Concerns Associated With Embryonic Stem Cell Research 
A major concern associated with human embryonic stem cell research, involving 
the first method of isolation, is the destruction of potential life.154   Responding to 
this argument, researchers remind critics that three-day old blastocysts used in the 
isolation process are not yet embryos.155  At the blastocyst stage, the likelihood that a 
particular stem cell will become part of the placenta, which will be discarded at birth, 
is equivalent to the likelihood that the same stem cell will develop into part of a 
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potential person.156  Many ethics committees, including those in the United States 
(the National Institutes of Health and the Human Embryo Research Panel), the 
United Kingdom, Australia, and Denmark, have referred to human embryos up to 
fourteen days old as “pre-embryos.”157  These committees recognize that before 
fourteen days there is absolutely no possible way to differentiate between the cells 
that will become part of the embryo and the cells that will become part of the 
placenta.158   Therefore, these countries have approved human embryonic research on 
“pre-embryos” up to fourteen days old.159 
Another major concern associated with human embryonic stem cell research 
centers around the second method of isolation.  Critics of human embryonic stem 
cell research feel the second method of isolation will encourage women to have 
abortions.160  This concern is completely unfounded.  The request for the donation of 
an aborted fetus is made only after the abortion procedure has been completed.161  
Second, the woman does not receive any compensation for the donation of an 
aborted fetus.162  The argument that this method of stem cell isolation causes abortion 
is as ridiculous and unfounded as arguing that organ transplantation causes 
murder.163   Scientists and supporters of human embryonic stem cell research suggest 
that those who oppose such research should view it as saving a life rather than 
ending a life.164 
Finally, the Supreme Court of the United States has determined that a fetus is not 
a “person” under the Constitution.165  Therefore, a fetus is not afforded any 
Constitutional rights.166  Additionally, in Roe v. Wade, the Supreme Court upheld a 
woman’s right to receive an abortion.167 
In 1995, due to enormous public pressure, Congress instituted a ban on the use of 
federal funds in human embryonic research.168  On January 19, 1999, the Department 
of Health and Human Services ruled that embryonic stem cells do not fall under the 
1995 Congressional ban on the use of federal funds in support of embryonic 
research.169  Recognizing the tremendous scientific and medical importance of 
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human embryonic stem cell research, Congress concluded that the benefits 
outweighed the concerns.170  Consequently, Congress now permits federal funds to 
be used in support of human embryonic stem cell research projects.171   
The importance of human embryonic stem cell research in the advancement of 
transplantation science is tremendous and clearly outweighs the concerns associated 
with this type of research.  The isolation of stem cells has given scientists the ability 
to ensure that in the future persons in need of organ transplants will not die waiting 
for an organ.  This discovery does not solve all the problems associated with organ 
transplants, although it has enabled scientists to look positively on the future of 
transplantation science.  Additionally, researchers feel that human embryonic stem 
cell research will revolutionize the treatment of degenerative diseases like 
Parkinson’s, Alzheimer’s, diabetes, heart disease, stroke, arthritis, birth defects, 
osteoporosis, spinal cord injuries, burns, and most cancers.172  Ultimately, over 140 
million Americans stand to benefit from human embryonic stem cell research 
therefore scientists need the freedom to continue their research.173     
V.  ETHICAL AND LEGAL CONCERNS ASSOCIATED WITH GENETIC RESEARCH 
The advances in genetic research are extremely important in the treatment and 
diagnosis of disease.  However, genetic research has raised some ethical and legal 
concerns.  The advances in the field of genetics have made vast amounts of personal 
genetic information available.  The availability of genetic information is the center of 
the debate over restrictions on genetic research.  Proponents of strict limitations on 
genetic research argue that the availability of genetic information can lead to 
breaches of privacy and fair employment and insurance practices.  Although these 
concerns are prevalent in the minds of most people, the current legislation 
encompasses all of these concerns. 
A.  Privacy and Genetic Research 
The most compelling concern associated with advances in genetic research is the 
effect on privacy rights.  The purpose of the Human Genome Project is to gain 
access to information locked in an individual’s genetic code.174  Many people believe 
this information is so personal, it should stay locked.175  Access to this personal 
genetic information will assist researchers in the detection, treatment, and prevention 
of disease.176  Recognizing the highly personal and sensitive nature of this 
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information, researchers agree it should be afforded special protection to ensure the 
individual donor’s privacy interests are not compromised.177 
People fear that once scientists unlock the genetic code, anyone will be able to 
gain access to this highly personal and sensitive genetic information.178  Genetic 
information is the pathway into an individual’s future, past, and present.179  Genetic 
information discloses a person’s traits, disease patterns and family history.180  
Consequently, if this information is not kept private, the wrong person could gain 
access into an individual’s future, past, and present.181 
Genetic information is considered to be highly sensitive and private for several 
reasons.  First, the information contained in a genetic code is largely unknown by the 
person in whose genetic material it was found.182  Therefore, if the wrong person 
gained access to this information, he would know more about the owner of the 
genetic material than the owner knows about himself.183  Second, genetic information 
discloses probabilistic health information about the individual’s family, especially 
parents, siblings, and children.184  Finally, because the DNA molecule is stable, once 
stored, it can become an infinite source of genetic information.185 
Because genetic material contains highly sensitive and personal genetic 
information, many fear that once it becomes available the donor’s privacy rights will 
be violated.  Although this is a valid concern, legislation has been developed to 
ensure that Americans do not have to sacrifice their Constitutionally protected right 
to privacy for advances in genetics.  The Genetic Privacy Act and the ELSAI 
Program have been developed to protect this privacy interest. 
B.  Employment Practices and Genetic Research 
Another issue raised by genetic research is the use of genetic information in 
employment practices.  Critics of the availability of genetic information believe that 
genetic test results and information will be used unfairly in employment practices.186  
Some fear that a discouraging genetic makeup will eliminate them from the job 
market.187  Furthermore, people fear that employers will begin to use genetic tests to 
screen employees for genetically desired or undesired traits.188  Finally, many fear 
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that negative genetic information will cause their employer to deny them insurance 
coverage.189 
There is some evidence that genetic information has been the basis for denying 
corporate insurance coverage.  For example, the father of an eight-year old girl 
suffering from PKU had a family group insurance plan through his employer.190  The 
young girl’s medical records indicated that she was on a low phenylalanine diet and 
was developing normally and healthy.191  Subsequent to her diagnosis, her father 
changed jobs and was denied insurance coverage by his new employer, because of 
her condition.192 
The issues associated with the use of genetic information in employment 
practices are significant; however, federal legislation has been developed to ensure 
that these issues are dealt with effectively.  For instance, in 1995 the Equal 
Employment Opportunity Commission broadened the Americans with Disabilities 
Act to address concerns raised by the use of genetic information in employment 
practices.193  Furthermore, many committees have been developed to ensure that 
employers do not abuse the availability of genetic information.194 
C.  Insurance Coverage 
The availability of genetic information has fueled concerns that it will be used by 
insurance providers in making coverage decisions.195  Insurance coverage is based on 
a theory of shared risks.196  Therefore, prior to offering coverage, an insurance 
company will appraise all potential risks of the individual or the group.197  Some of 
the risk factors used in coverage selection are age, present health, and the potential 
for future disease.198  The presence of certain health conditions can result in higher 
premiums or complete denial of coverage.199  Fortunately, most health conditions 
develop later in life; therefore people afflicted with these conditions can secure 
insurance coverage, at a reasonable rate, prior to the detection of the disease.200 
The availability of genetic information has the potential to change the way in 
which insurance providers determine coverage.201  First, genetic tests will enable 
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physicians to determine the presence of a disease prior to the onset of symptoms.202  
Insurance providers may see the presence of a potential disease as too great a risk.203  
Therefore, they may begin to deny coverage or charge extremely high premiums to 
people who are not sick and who may never become sick.204 
There are several cases involving individuals who have been denied insurance 
coverage based on their genetic makeup.  A woman who questioned her gynecologist 
about a family history of Huntington’s Disease was denied coverage.205  Likewise a 
salesman with a mild, stable, barely perceptible genetic characteristic was denied 
insurance coverage.206  A family was excluded from coverage when their insurance 
provider discovered that the son suffered from a form of genetic mental 
retardation.207  The insurance provider denied coverage to the entire family, even 
though it knew that the genetic disorder did not affect his health and was unlikely to 
be present in any of the female family members.208  Although these cases are 
disturbing, evidence establishes that insurance providers rarely use genetic 
information to determine whether or not to provide an individual or group with 
insurance coverage.209 
The concerns associated with the use of genetic information by insurance 
providers are significant; however, federal legislation has been developed to curb 
this problem.  In 1996, the Health Insurance Portability and Accountability Act was 
passed to ensure that insurance providers do not make coverage decisions based on 
genetic information.210  Focusing on the use of genetic information by insurance 
providers, the House of Representatives recently enacted the Genetic Privacy and 
Nondiscrimination Act.  Additionally, the National Institute of Health, the 
Department of Energy Working Group, and the National Action Plan on Breast 
Cancer working jointly have made a series of policy recommendations on the use of 
genetic information and insurance coverage for federal and state legislatures.211 
VI.  FEDERAL LEGISLATION 
In response to the aforementioned concerns, several pieces of legislation have 
been developed and amended.  The Genetic Privacy Act was created to deal with the 
privacy issues associated with the availability of genetic information.212  Congress 
recently enacted the Genetic Privacy and Nondiscrimination Act to restrict the use of 
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genetic information by insurance and health care providers and in employment 
practices.213  The Equal Employment Opportunity Commission broadened the scope 
of the Americans with Disabilities Act, thereby prohibiting employers from misusing 
genetic information.214  The Health Insurance Portability and Accountability Act was 
enacted to ensure the fair use of genetic information by insurance providers.215  The 
present legislative restrictions on the use of genetic information are ample enough to 
overcome the current problems associated with genetic research. 
A.  The Genetic Privacy Act 
The Genetic Privacy Act [hereinafter “GPA”] has three common goals.  First, the 
GPA seeks to encourage a greater dissemination of information to patients and 
donors of genetic material.216  Second, the GPA assures the protection of genetic 
information, while promoting continued research and experimentation in the field of 
genetics.217  Finally, the GPA encourages individuals to supply genetic samples for 
analysis and research.218   
The underlying goal of the GPA is to protect the sample source’s219 interest in his 
own genetic material and information.220   The drafters of the GPA also realize the 
importance of continued genetic research in the discovery and treatment of 
disease.221  Therefore, the GPA takes the proper steps to protect the sample source’s 
interest in his genetic material without discouraging continued advancements in 
genetics. 
1.  The GPA Adequately Monitors the Collection, Analysis and Disclosure  
of Genetic Material. 
Sections 101(a) and 102(a) of the GPA prohibit the collection and genetic 
analysis of an individually identifiable DNA sample without the written consent 
from the sample source or a representative of the sample source.222  Section 103(a) of 
the GPA outlines the requirements for a valid written authorization for the collection 
and analysis of a DNA sample.223  Pursuant to Section 103(a) of the GPA, a valid 
authorization contains the following: 1) a writing signed and dated by the sample 
source or the sample source’s representative; 2) the identity of the individual 
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collecting or requesting the genetic sample;  3) the identity of the facility where the 
DNA sample will be analyzed and stored; 4) the manner in which the DNA will be 
collected; 5) a description of all authorized uses of the DNA sample; 6) a statement 
regarding storage of the DNA after completion of the genetic analysis; and, 7) a 
provision that permits the sample source or sample source’s representative to 
prohibit the use of the DNA sample for research or commercial purposes.224  The 
GPA provides for an extremely strict written authorization requirement for the 
collection and analysis of a DNA sample.225  This written authorization requirement 
allows for enhanced dissemination of information from the researcher to the patient, 
sample source, or the sample source’s representative.226  Furthermore, §§ 101, 102, 
and 103 ensure that the sample source or the sample source’s representative has 
complete control over the DNA sample.227 
Section 111(a) of the GPA prohibits any person from communicating or 
disclosing private genetic information without written authorization from the sample 
source or a representative of the sample source.228  Section 112(a) of the GPA 
provides that a valid disclosure authorization contains the following: 1) a writing 
signed and dated by the sample source or a representative of the sample source;  2) 
the identity of the individual granting the authorization and the individual’s 
relationship to the sample source (if not sample source); 3) the identity of the person 
permitted to make the disclosure; 4) a description of the specific genetic material to 
be disclosed; 5) the identity of the person to whom the information is to be disclosed; 
6) a description of the purpose for disclosure; 7) the date upon which the 
authorization expires (cannot be longer than thirty days after grant of authorization); 
and, 8) a statement that the sample source or sample source’s representative can 
revoke the authorization at any time.229   
Analogous to §§ 101(a) and 102(a) of the GPA, § 111(a) provides a stringent 
written requirement for the disclosure of genetic information.  The written disclosure 
requirement ensures the privacy of the sample source by giving him complete control 
over the disclosure of his genetic information.230  While protecting the privacy 
interest of the sample source, the GPA provides researchers with the flexibility they 
need to access a patient’s genetic information.231 
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2.  The GPA Confers a Federal Property Right in the DNA Sample to  
the Sample Source. 
Pursuant to § 104(a) of the GPA, the sample source or the sample source’s 
representative receives a federal property right in his DNA sample.232  Because the 
sample source is the sole owner of his genetic material, he can order the destruction 
of the sample at any time.233  The effect of this provision is two-fold.  First, § 104(a) 
of the GPA protects the privacy interest the sample source has in his genetic 
material.234  This privacy interest is protected because the sample source or owner 
has complete control over the how the sample will be used.  Second, § 104(a) of the 
GPA promotes continued developments in genetic research.235  The sample source’s 
property right in his DNA sample gives those hesitant about participating in research 
projects the incentive to do so.236 
3.  Effectiveness of the GPA in Dealing with Issues Raised by Genetic Research. 
The GPA adequately deals with the privacy concerns associated with advances in 
genetic research.  The GPA provides a strict written authorization requirement for 
the collection, analysis, and disclosure of genetic material.  The GPA confers a 
federal property right in the DNA sample to the sample source, thereby giving the 
sample source complete control over his genetic material.  The Genetic Privacy Act 
effectively suppresses concerns raised by the advances in genetic research, while 
promoting continued research and development in the field of genetics. 
B.  Genetic Privacy and Nondiscrimination Act of 1999 
The Genetic Privacy and Nondiscrimination Act of 1999 [hereinafter “GPNA”] 
was passed by the  House of Representatives in the 106th Congress.237  The purpose 
of the GPNA is to establish limitations on the disclosure and use of genetic 
information by insurance providers and employers.238  By restricting the use and 
disclosure of genetic information, the GPNA safeguards an individual’s 
Constitutionally protected right to privacy. 
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1.  GPNA Prohibits Health Insurance Discrimination Based on an Individual’s 
Genetic Information. 
Section 2 of the GPNA amends the Public Health and Service Act [hereinafter 
“PHSA”] to prohibit insurance discrimination based on genetic information.239    
Additionally, § 2(B) of the GPNA prohibits the use and disclosure of genetic 
information without the individual owner’s consent.240  This section amends Subpart 
2 of Part A of Title XXVII of the PHSA by adding an additional section.  Section 
2707 (section added by the GPNA) of the PHSA provides, in pertinent part:  
A group health plan, and a health insurer offering health insurance 
coverage in connection with a group health plan, may not use genetic 
information to reject, deny, limit, cancel, refuse to renew, establish 
differential rates on premium payments for, or otherwise affect benefits 
provided under the plan or health insurance coverage offered in 
connection with the plan.241 
Additionally, § 2707 of the PHSA states that a health insurance provider may not 
disclose or be compelled to disclose (even through a subpoena) an individual’s 
genetic information without specific authorization from the individual or a legal 
representative of the individual.242  The authorization must be in writing and must 
contain the following: 1) a description of the information to be disclosed; 2) the 
name of the individual or entity to which the information is to be disclosed; and, 3)  
the purpose of the disclosure.243  The same amendments were made to Subpart B of 
part 7 of Title I of the Employment Retirement Income Security Act of 1974.244 
The GPNA effectively addresses issues raised about the use of genetic 
information by insurance providers.  The GPNA does not permit insurance providers 
to make coverage decisions based on an individual’s genetic information.  
Furthermore, the GPNA prohibits the disclosure of such information without the 
expressed written consent of the owner.  The GPNA, in accordance with the GPA, 
ensures that advances in genetic information will not punish American citizens. 
2.  The GPNA prohibits the use of Genetic Information in Employment Practices. 
Section 3 of the GPNA prohibits the use of genetic information in employment 
practices.245  Section 3(a)(1)(A)(B) provides, in pertinent part:  
[I]t shall be unlawful employment practice for an employer (A) to attempt 
to acquire, to acquire, or to use the genetic information of an employee or 
applicant for employment, or (B) to require a genetic test of an employee 
or applicant for employment, for the purpose of distinguishing among 
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employees or applicants for employment or for the purpose of 
discriminating against or restricting any right or benefit otherwise due or 
available to an employee or applicant for employment, in connection with 
any matter relating to employment or employment opportunities, 
including terms and conditions of employment, privileges and benefits for 
employees, and termination of employment.246 
Section 3 of the GPNA also contains a provision making it unlawful for an 
employer to disclose or to allow an unauthorized individual to gain access to 
another’s genetic information.247  The GPNA further provides that § 3 of this act is 
enforceable under §§ 705-709 of the Civil Rights Act.248 
The GPNA adequately addresses concerns regarding the use of genetic 
information in employment practices.  For all intents and purposes, the GPNA 
prohibits the use of genetic information in employment practices.249  In fact, the 
GPNA makes the use of genetic information in employment practices illegal.250  The 
GPNA is an effective measure enacted by the House of Representatives to suppress 
concerns raised by advances in genetics.   
C.  The Americans With Disabilities Act 
On March 14, 1995, the Equal Employment Opportunity Commission 
[hereinafter “EEOC”] determined that individuals who are subjected to 
discrimination based on genetic information relating to disease or other disorders are 
considered disabled.251  Because the EEOC recognizes these individuals as disabled, 
they fall under the purview the Americans with Disabilities Act [hereinafter 
“ADA”].252   Allowing employees who have been discriminated against based on 
their genetic information to bring a cause of action under the ADA will dissuade 
employers from misusing genetic information in employment practices.   
D.  The Health Insurance Portability and Accountability Act 
Congress enacted the Health Insurance Portability and Accountability Act 
[hereinafter “HIPAA”] in order to address concerns associated with the use of 
genetic information by insurance providers.253  HIPAA is codified in various sections 
of 26 U.S.C., 29 U.S.C., and 42 U.S.C.254 
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Section 1182(a)(1)(E), Title 29 of the United States Code prohibits a health 
insurer offering a group insurance plan from establishing rules of eligibility based on 
genetic information.255  Section 1182(b)(1) states that an insurance provider offering 
a group plan is not permitted to require an individual to pay a higher premium than 
those similarly situated, based solely on the individual’s health information.256  
Essentially, HIPAA prohibits insurers from using genetic information to deny or 
limit health insurance coverage.257  Thus, HIPAA protects many Americans from 
losing health insurance coverage based on genetic information, whether it is gained 
from genetic testing or medical history.258  
HIPAA, in connection with the GPNA, adequately addresses concerns associated 
with the use of genetic information by insurance providers.  The benefits gained 
through genetic research clearly outweigh the concerns, thus the present limitations 
placed on the field are sufficient. 
VII.  PROGRAMS DEVELOPED TO DEAL WITH LEGAL AND ETHICAL CONCERNS 
In addition to the federal legislation created to quell the ethical and legal artery 
associated with genetic research, several committees have been developed.  The 
ELSIP and the National Institutes of Health and Department of Energy Working 
Groups are two programs that have been created to address the concerns raised by 
genetic research. 
The United States Department of Energy [hereinafter “DOE”] and the National 
Institutes of Health [hereinafter “NIH”] have devoted three to five percent of the 
annual Human Genome Budget toward the study of ELSI raised by the availability of 
genetic information.259  The main goals of the ELSI programs are to facilitate 
medical and scientific research in the field of genetics, while promoting education 
and the development of related medical and public policies.260  The ELSI programs 
are in place to ensure that genetic information is not misused.261  Specifically, the 
ELSI programs focus on maintaining privacy and fair employment and insurance 
practices.262  Additionally, ELSI frequently joins with the NIH and the DOE to make 
policy recommendations on the importance of protecting genetic information to 
federal and state policy makers.263  For example in 1995, the NIH-DOE ELSI 
Working Group and the National Action Plan on Breast Cancer developed a series of 
policy recommendations to prevent the unfair use of genetic information by 
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insurance providers and employers.264   These programs have been created to 
safeguard the interests of Americans, and to ensure that individuals do not have to 
exchange their rights to privacy, fair insurance and employment practices for 
advances in genetic research. 
VIII.  CONCLUSION 
The advances being made in the field of genetics are miraculous.  Furthermore, 
these advances are extremely beneficial to scientists in the study of disease.  
Researchers feel the completion of the Human Genome Project will unlock many 
mysteries in the study of human diseases.  Although the completion of this project 
will lead scientists one step closer to the treatment of thousands of fatal and 
debilitating diseases, the project will also make genetic information completely 
accessible.  Because of the personal and sensitive nature of this information, people 
fear that they will lose their right to privacy and to fair employment and insurance 
practices.  Federal legislation is in place to suppress these concerns.265  Additionally, 
programs are in place to make continued policy recommendations to state and 
federal policy makers.266  This Note has established that the present limitations 
placed on genetic research are sufficient to suppress the concerns associated with this 
research.  Furthermore, this Note has illustrated that the benefits of genetic research 
clearly outweigh those concerns thus scientists should be free to continue their 
research without further restrictions. 
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